Equities

Pharmesis International Ltd

Pharmesis International Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SGD)0.625
  • Today's Change0.055 / 9.65%
  • Shares traded1.70k
  • 1 Year change+610.23%
  • Beta0.0749
Data delayed at least 10 minutes, as of Nov 15 2024 03:33 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Pharmesis International Ltd. is a Singapore-based investment holding company. The Company is a pharmaceutical company engaged in the manufacturing of pharmaceutical products, including western medicine in the form of tablets and granules, among others, and traditional Chinese medicine (TCM) formulated products for the treatment of illnesses relating to the liver and gall bladder. It operates in three segments: Western drugs, which refers mainly to chemically formulated drugs marketed under the Kinna brand; TCM formulated drugs, which includes TCM marketed under the Longlife brand, and Distribution, which includes agency products and internally manufactured products marketed through the distribution arm. Its main products are ATT, Gulin Gansu and Er Ding granules. Its subsidiary, Chengdu Kinna Pharmaceutical Co., Ltd, is engaged in the development, manufacture, packaging and sale of western medicines and health tonic products.

  • Revenue in SGD (TTM)7.77m
  • Net income in SGD-1.38m
  • Incorporated2003
  • Employees--
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Regent Pacific Group Ltd343.24k-20.82m17.39m19.00------50.66-0.527-0.5270.0087-0.13880.0288--11.86116,709.00-174.72-50.00-279.01-59.04-----6,067.06-2,685.21---152.22----574.47-44.7231.24---50.60--
Valerio Therapeutics SA2.68m-27.87m17.51m38.00--3.06--6.54-0.1233-0.12330.01190.02610.0515--0.512199,421.05-53.59-34.19-76.22-40.5974.7584.11-1,040.66-586.99---188.640.7662--24.74-21.73-4.00--32.39--
Vivesto AB0.00-12.11m17.81m4.00--0.8127-----0.1839-0.18390.000.33280.00----0.00-39.70---43.32--------------0.00---100.00--64.80------
Immunoprecise Antibodies Ltd23.07m-26.44m17.85m102.00--0.5372--0.7737-0.7421-0.74210.65520.8560.35466.126.16---40.63-26.70-46.68-30.3148.2156.13-114.58-85.720.8189-134.720.3289--18.6517.54-2.32--16.71--
Corline Biomedical AB2.15m-790.31k17.88m14.00--1.67--8.33-0.3005-0.30050.81654.070.1729--4.691,349,769.00-6.36-5.71-7.13-6.24141.25128.60-36.80-38.46---306.520.00--6.2874.14-177.67--62.51--
Ind Swift Ltd74.52m6.39m17.94m1.67k2.80--1.710.24077.427.4286.37-------------0.902----45.6345.728.58-1.44--0.1318----22.2111.68-45.3411.6815.24--
Pharmesis International Ltd.7.77m-1.38m18.07m----1.94--2.32-0.0495-0.04950.27940.29430.51171.657.48---10.02-6.47-15.28-10.2141.3048.72-19.59-13.390.4725-8.230.2363---9.40-6.64-39.27---32.66--
Onconetix Inc1.97m-71.51m18.20m12.00------9.24-104.90-104.902.8950.920.03283.455.30121,979.20-119.09---215.11---57.21---3,629.24--0.091-11.870.2984-------176.78------
Devonian Health Group Inc9.34m-3.03m18.45m6.00--1.44--1.98-0.0216-0.02160.06650.090.442333.072.321,625,238.00-14.37-21.02-23.15-23.9630.9529.96-32.50-131.971.06-9.410.1406--1.74-5.83-33.39------
Data as of Nov 15 2024. Currency figures normalised to Pharmesis International Ltd's reporting currency: Singapore Dollar SGD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.